| 臺大學術典藏 |
2022-02-14T07:10:39Z |
Loss of SFRP1 expression is a key progression event in gastrointestinal stromal tumor pathogenesis
|
Liang C.-W.; Yang C.-Y.; Flavin R.; Fletcher J.A.; Lu T.-P.; Lai I.-R.; Li Y.-I.; YIH-LEONG CHANG; Lee J.-C. |
| 臺大學術典藏 |
2022-02-14T07:10:38Z |
Loss of SFRP1 expression is a key progression event in gastrointestinal stromal tumor pathogenesis
|
Liang C.-W.; Yang C.-Y.; Flavin R.; Fletcher J.A.; Lu T.-P.; Lai I.-R.; Li Y.-I.; Chang Y.-L.; JEN-CHIEH LEE |
| 臺大學術典藏 |
2021-05-21T07:46:15Z |
Loss of SFRP1 expression is a key progression event in gastrointestinal stromal tumor pathogenesis
|
Liang C.-W.;Yang C.-Y.;Flavin R.;Fletcher J.A.;Tzu-Pin Lu;Lai I.-R.;Li Y.-I.;Chang Y.-L.;Lee J.-C.; Liang C.-W.; Yang C.-Y.; Flavin R.; Fletcher J.A.; TZU-PIN LU; Lai I.-R.; Li Y.-I.; Chang Y.-L.; Lee J.-C. |
| 臺大學術典藏 |
2021-04-27T01:56:34Z |
Loss of SFRP1 expression is a key progression event in gastrointestinal stromal tumor pathogenesis
|
Liang C.-W.; CHING-YAO YANG; Flavin R.; Fletcher J.A.; Lu T.-P.; Lai I.-R.; Li Y.-I.; Chang Y.-L.; Lee J.-C. |
| 臺大學術典藏 |
2021-03-08T08:06:07Z |
Loss of SFRP1 expression is a key progression event in gastrointestinal stromal tumor pathogenesis
|
Liang C.-W.; Yang C.-Y.; Flavin R.; Fletcher J.A.; Lu T.-P.; I-RUE LAI; Li Y.-I.; Chang Y.-L.; Lee J.-C. |
| 臺大學術典藏 |
2020-03-07T06:52:13Z |
Dystrophin is a tumor suppressor in human cancers with myogenic programs
|
Wang Y.; Marino-Enriquez A.; Bennett R.R.; Zhu M.; Shen Y.; Eilers G.; JEN-CHIEH LEE; Henze J.; Fletcher B.S.; Gu Z.; Fox E.A.; Antonescu C.R.; Fletcher C.D.M.; Guo X.; Raut C.P.; Demetri G.D.; Van De Rijn M.; Ordog T.; Kunkel L.M.; Fletcher J.A. |
| 臺大學術典藏 |
2020-03-07T06:52:12Z |
KRAS and KIT gatekeeper mutations confer polyclonal primary imatinib resistance in GI stromal tumors: Relevance of concomitant phosphatidylinositol 3-kinase/AKT dysregulation
|
Serrano C.;Wang Y.;Mariño-Enríquez A;Jen-Chieh Lee;Ravegnini G.;Morgan J.A.;Bertagnolli M.M.;Beadling C.;Demetri G.D.;Corless C.L.;Heinrich M.C.;Fletcher J.A.; Serrano C.; Wang Y.; Mariño-Enríquez A.; JEN-CHIEH LEE; Ravegnini G.; Morgan J.A.; Bertagnolli M.M.; Beadling C.; Demetri G.D.; Corless C.L.; Heinrich M.C.; Fletcher J.A. |
| 臺大學術典藏 |
2020-03-07T06:52:10Z |
ALK oncoproteins in atypical inflammatory myofibroblastic tumours: novel RRBP1-ALK fusions in epithelioid inflammatory myofibroblastic sarcoma
|
Jen-Chieh Lee;Li C.-F.;Huang H.-Y.;Zhu M.-J.;Mari?o-Enr?quez A.;Lee C.-T.;Ou W.-B.;Hornick J.L.;Fletcher J.A.; JEN-CHIEH LEE; Li C.-F.; Huang H.-Y.; Zhu M.-J.; Mariño-Enríquez A.; Lee C.-T.; Ou W.-B.; Hornick J.L.; Fletcher J.A. |
| 臺大學術典藏 |
2020-03-05T06:38:59Z |
Dystrophin is a tumor suppressor in human cancers with myogenic programs
|
Wang Y.; Marino-Enriquez A.; Bennett R.R.; Zhu M.; Shen Y.; Eilers G.; JEN-CHIEH LEE; Henze J.; Fletcher B.S.; Gu Z.; Fox E.A.; Antonescu C.R.; Fletcher C.D.M.; Guo X.; Raut C.P.; Demetri G.D.; Van De Rijn M.; Ordog T.; Kunkel L.M.; Fletcher J.A. |
| 臺大學術典藏 |
2020-03-05T06:38:56Z |
ALK oncoproteins in atypical inflammatory myofibroblastic tumours: novel RRBP1-ALK fusions in epithelioid inflammatory myofibroblastic sarcoma
|
Fletcher J.A.; Hornick J.L.; Ou W.-B.; Mari?o-Enr?quez A.; Lee C.-T.; Huang H.-Y.; Zhu M.-J.; Li C.-F.; JEN-CHIEH LEE |
| 臺大學術典藏 |
2020-02-20T02:57:06Z |
Integrating bioinformatics and clinicopathological research of gastrointestinal stromal tumors: Identification of aurora kinase a as a poor risk marker
|
Yen C.-C.; Yeh C.-N.; Cheng C.-T.; Jung S.-M.; Huang S.-C.; Chang T.-W.; Jan Y.-Y.; Tzeng C.-H.; Chao T.-C.; Chen Y.-Y.; CHING-YAO YANG; Ho C.-L.; Fletcher J.A. |
| 國立成功大學 |
2018 |
BPR1J373, a novel multitargeted kinase inhibitor, effectively suppresses the growth of gastrointestinal stromal tumor
|
Tsai, H.-J.;Jiaang, W.-T.;Shih, N.-Y.;Fletcher, J.A.;Lin, M.-J.;Yang, M.-Y.;Chen, Chen C.-T.;Hsu, T.-A.J.;Wu, C.-C.;Lin, H.-Y.;Chen, L.-T. |
| 國立成功大學 |
2017 |
ALK oncoproteins in atypical inflammatory myofibroblastic tumours: novel RRBP1-ALK fusions in epithelioid inflammatory myofibroblastic sarcoma
|
Lee, J.-C.;Li, C.-F.;Huang, Huang H.-Y.;Zhu, M.-J.;Mari�o-Enr�quez, A.;Lee, C.-T.;Ou, W.-B.;Hornick, J.L.;Fletcher, J.A. |
| 臺大學術典藏 |
2015 |
KRAS and KIT gatekeeper mutations confer polyclonal primary imatinib resistance in GI stromal tumors: Relevance of concomitant phosphatidylinositol 3-kinase/AKT dysregulation
|
Serrano C.; Wang Y.; Mari?o-Enr?quez A.; JEN-CHIEH LEE; Ravegnini G.; Morgan J.A.; Bertagnolli M.M.; Beadling C.; Demetri G.D.; Corless C.L.; Heinrich M.C.; Fletcher J.A. |
